Daniel George
Medical oncologist and clinical investigator at Duke Cancer Institute with expertise in prostate cancer biology and biomarkers, presenting on PTEN deficiency and clinical implications.
Best podcasts with Daniel George
Ranked by the Snipd community
Mar 30, 2026 • 1h 29min
AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Prof Karim Fizazi, an academic oncologist focused on genitourinary cancers, and Dr Daniel George, a prostate cancer clinical investigator at Duke, discuss AKT inhibition and PTEN deficiency in metastatic prostate cancer. They cover biomarker testing methods, rationale for AKT targeting, trial results including CAPItello-281, toxicity management, timing of therapy, and clinical integration of AKT inhibitors.
